No connection between ARBs and cancer
In 2010, a controversial analysis suggested that angiotensin-receptor blockers (ARBs) increased the risk of developing cancer, especially lung cancer. Not so, says an FDA safety alert issued in June 2011.
ARBs are widely used to treat high blood pressure. They include azilsartan medoxomil (Edarbi), candesartan (Atacand), eprosartan (Teveten), irbesartan (Avapro), losartan (Cozaar, generic), olmesartan (Benicar), telmisartan (Micardis), and valsartan (Diovan). Several combination drugs include an ARB plus a diuretic or a calcium-channel blocker.
To continue reading this article, you must log in.
Subscribe to Harvard Health Online for immediate access to health news and information from Harvard Medical School.
- Research health conditions
- Check your symptoms
- Prepare for a doctor's visit or test
- Find the best treatments and procedures for you
- Explore options for better nutrition and exercise
I'd like to receive access to Harvard Health Online for only $4.99 a month.
Sign Me UpAlready a member? Login ».
Disclaimer:
As a service to our readers, Harvard Health Publishing provides access to our library of archived content. Please note the date of last review or update on all articles.
No content on this site, regardless of date, should ever be used as a substitute for direct medical advice from your doctor or other qualified clinician.
